Dominique Genre

ORCID: 0000-0003-1736-4612
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Treatment and Pharmacology
  • Patient-Provider Communication in Healthcare
  • Health Systems, Economic Evaluations, Quality of Life
  • Ethics in Clinical Research
  • Cancer survivorship and care
  • Health, Medicine and Society
  • Neutropenia and Cancer Infections
  • Palliative Care and End-of-Life Issues
  • Pancreatic and Hepatic Oncology Research
  • Healthcare Systems and Practices
  • Childhood Cancer Survivors' Quality of Life
  • Chemotherapy-related skin toxicity
  • Cancer Cells and Metastasis
  • Breast Cancer Treatment Studies
  • Lung Cancer Treatments and Mutations
  • Economic and Financial Impacts of Cancer
  • Hematopoietic Stem Cell Transplantation
  • Social Media in Health Education
  • Retinoids in leukemia and cellular processes
  • Chronic Lymphocytic Leukemia Research
  • Clinical practice guidelines implementation
  • Lymphoma Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia research
  • Cancer-related cognitive impairment studies
  • Cancer Genomics and Diagnostics

Institut Paoli-Calmettes
2003-2019

Inserm
1997-2017

Glasgow Caledonian University
2017

Economic & Social Sciences, Health Systems & Medical Informatics
1997-2017

Aix-Marseille Université
1997-2017

Institut Pprime
1997-2017

Institut de Recherche pour le Développement
2017

Centre Provence-Alpes-Côte d'Azur
2017

Centre de Recherche en Cancérologie de Marseille
1997-2012

Délégation Provence et Corse
2012

Total mesorectal excision is the standard surgical treatment for mid- and low-rectal cancer. Laparoscopy represents a clear leap forward in management of rectal cancer patients, offering significant improvements post-operative measures such as pain, first bowel movement, hospital length stay. However, there are still some limits to its applications, especially difficult cases. Such cases may entail either conversion an open procedure or positive resection margins. Transanal endoscopic...

10.1186/s12885-017-3200-1 article EN cc-by BMC Cancer 2017-04-11

The current Phase II study investigated the clinical benefit, impact on quality of life (QOL), and tolerability weekly docetaxel in symptomatic patients with metastatic hormone-refractory prostate carcinoma (HRPC).Patients received 35 mg/m(2) intravenously for 6 consecutive weeks followed by a 2-week rest repeatedly maximum 24 treatment. Clinical benefit evaluations, based Karnofsky performance status (KPS) pain, were assessed during therapy. A response was defined as sustained (> or =...

10.1002/cncr.11687 article EN Cancer 2003-09-17

Abstract BACKGROUND: Information is crucial for increasing the patients' empowerment and autonomy in relevant decision‐making processes, especially malignant diseases. However, extent to which information should be delivered debated. The objective of this study was assess impact providing systematic full access (SFA) medical record on anxiety, quality life, satisfaction. METHODS: Patients with newly diagnosed breast cancer, colon or lymphoma who had received adjuvant chemotherapy an...

10.1002/cncr.26083 article EN Cancer 2011-05-23

BACKGROUND This study was designed to investigate the personal experience of patients with nonmetastatic breast carcinoma who were treated concurrent administration radiotherapy and chemotherapy in terms side effects quality life (QL). METHODS One hundred nine carcinoma, recruited between May 1995 February 1997, included a protocol combining mitoxantrone cyclophosphamide, administered intravenously 4 cycles 21 days, concomitant radiotherapy. Side treatment its impact on patients' daily lives...

10.1002/(sici)1097-0142(19990515)85:10<2190::aid-cncr13>3.0.co;2-p article EN Cancer 1999-05-15

Participants are showing great interest these days in obtaining the results of clinical trials. The aim this study was to assess patients' uptake and understanding trial which they have participated impact a letter offering patients possibility consulting on specific website. Breast cancer participating efficacy Trastuzumab were randomly subdivided into an Internet group (who received invitation) control did not receive it). Among 115 HER2-positive women from 21 centres, 107 (93%) answered...

10.1038/sj.bjc.6605592 article EN cc-by-nc-sa British Journal of Cancer 2010-03-01

The aim of this study was to investigate the feasibility and acceptability a repeated measurement 5 major side effects (pain, nausea, vomiting, anxiety, fatigue) experienced by patients during an entire course chemotherapy. Forty-nine inpatients receiving intravenous chemotherapy in medical oncology department Institut Paoli-Calmettes (Marseilles, France) were included study. At entry every 12 hours from beginning course, nurses assessed symptoms using Visual Analogic Scales (except for...

10.1097/00002820-200312000-00006 article EN Cancer Nursing 2003-12-01

Cancer patients participating in randomized controlled trials (RCTs) have not been found to better clinical outcomes than other patients. Our objective was assess the impact of RCTs on patients' satisfaction with care.A prospective study carried out a cohort women breast cancer (N = 455) divided into those invited participate an RCT (201 acceptances, 66 refusals) and comparable control group (n 188). All underwent same treatment (fluorouracil, epirubicin, cyclophosphamide 100 mg/m2 for six...

10.1200/jco.2006.08.9367 article EN Journal of Clinical Oncology 2007-05-30

Purpose We conducted a phase 1 trial to determine the maximum tolerated dose (MTD) of weekly docetaxel delivered concurrently with radiation therapy for treatment locally advanced adenocarcinoma pancreas. Patients and Methods Thirteen patients histologically proven non-resectable pancreas were enrolled in this study. received 4 doses by 1-hour intravenous (IV) infusion 40 Gy external beam during weeks. who stabilized or response, 2 additional cycles 10 boost radiotherapy. Doses escalated at...

10.1097/00006676-200310000-00003 article EN Pancreas 2003-09-26

Preclinical works have suggested cytotoxic chemotherapies may increase the number of cancer stem cells (CSC) whereas angiogenesis inhibition decrease CSC proliferation. We developed a proof concept clinical trial to explore bevacizumab activity on breast CSC. Breast patients requiring preoperative chemotherapy were included in this open-label, randomized, prospective, multicenter phase II trial. All received FEC-docetaxel combination, and randomized experimental arm concomitant bevacizumab....

10.3390/jcm8050612 article EN Journal of Clinical Medicine 2019-05-06

Background. The past decades have seen advances in cancer treatments terms of toxicity and side effects but progress the treatment advanced has been modest. New drugs emerged improving progression free survival with little impact on overall survival, raising questions about criteria which to base decisions grant marketing authorizations authorization procedure itself. For be fair, transparent accountable, it is necessary consider views those relevant expertise experience. Methods. We...

10.1177/0272989x17691953 article EN Medical Decision Making 2017-02-15
Coming Soon ...